

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.
In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail

(Translation)

March 17, 2022

To: Shareholders,

Company Name: Renascience Inc.
Name of Representative: Koji Naito, President and CEO
(Code: 4889 TSE Mothers)
Inquiries: Kazuhiro Ikeda, Diector, CFO

Announcement of Collaboration Agreement
with Tokyo Medical and Dental University Hospital

At a board meeting on March 17, 2022, the Board of Directors of the Company resolved to enter into a collaboration agreement with Tokyo Medical and Dental University Hospital to conduct a clinical study to explore the efficacy and safety of the PAI-1 inhibitor in patients with FGF23-related hypophosphatemic rickets.

1. Background and outline of the collaboration agreement

From a collaborative study with Northwestern University in the United States, the Company has findings (non-clinical studies) suggesting that the PAI-1 inhibitor RS5614 is effective as a treatment for FGF23-associated hypophosphatemic rickets (*Science Advances* 2017; 3: e1603259). Therefore, the Company entered into a collaboration agreement with Tokyo Medical and Dental University Hospital to conduct a clinical study to explore the efficacy and safety of RS5614, the PAI-1 inhibitor, in patients with FGF23-related hypophosphatemic rickets.

2. Outline of the collaboration partner

(1) name	Tokyo Medical and Dental University Hospital*.
(2) location	1-5-45 Yushima, Bunkyo-ku, Tokyo
(3) Title and name of representative	Hospital Director Shinichi Uchida
(4) Relationship with Tokyo Medical and Dental University Hospital	To date, Tokyo Medical and Dental University and the Company have conducted joint research on the efficacy and safety of the PAI-1 inhibitor and on the medical application of pyridoxamine. None of the capital relationship, personnel relationship, or related party status is applicable.

*Tokyo Medical and Dental University Hospital was established on October 1, 2021 by integrating the Hospital attached to the Faculty of Medicine and the Hospital attached to the Faculty of Dentistry of Tokyo Medical and Dental University.

(Reference) Outline of Tokyo Medical and Dental University

(1) name	Tokyo Medical and Dental University
(2) location	1-5-45 Yushima, Bunkyo-ku, Tokyo
(3) Title and name of representative	President Yujiro Tanaka

(4)	Capital stock	75,590,586 thousand yen		
(5)	Date of Establishment	August 1946.		
(6)	Relationship with Tokyo Medical and Dental University	Currently, the Company subcontracts the clinical research of pyridoxamine to Tokyo Medical and Dental University. There are no relevant matters regarding capital relationship, personal relationship, or related party status.		
(7)	Financial position and business results of Tokyo Medical and Dental University for the past three years			
	Accounting period	Year ending March 2019	Year ending March 2020	Year ending March 2021
	Net assets	120,989,559 thousand yen	122,578,322 thousand yen	126,093,233 thousand yen
	Total assets	154,518,170 thousand yen	159,613,342 thousand yen	164,137,491 thousand yen
	Ordinary revenue	60,169,733 thousand yen	62,971,797 thousand yen	65,446,449 thousand yen
	Ordinary income	1,974,227 thousand yen	3,279,689 thousand yen	5,079,400 thousand yen
	Current net income	1,659,198 thousand yen	3,160,192 thousand yen	5,089,870 thousand yen
	Current gross income	1,659,198 thousand yen	3,160,192 thousand yen	5,089,870 thousand yen

3. Schedule

(1)	Date of the internal approval	March 17, 2022
(2)	Date of execution of the agreement	March 17, 2022
(3)	Date of the business commencement	March 17, 2022

4. Outlook for the future

There is no change in the forecast of financial results for the fiscal year ended March, 2022 as a result of this matter.

End